A bipartisan group of lawmakers is urging the Food and Drug Administration to close a regulatory loophole involving peptides, according to a STAT report. The story, published in the D.C. Diagnosis newsletter, frames the effort as a health policy matter with ties to Eli Lilly and the broader obesity drug landscape.
Details of the proposed rule change or the specific peptides in question were not included in the available text. The report notes only that the lawmakers have made the request to the FDA, and that the topic is categorized under Congress, Eli Lilly, obesity, and policy.
The development highlights ongoing tensions around how peptide-based products are regulated, particularly as demand for obesity treatments grows. Without further specifics from the source, the exact scope of the loophole and the lawmakers' proposed fix remain unclear.